- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Brii Biosciences Ltd (2137)
Brii Biosciences Ltd stock price live, this page displays HK 2137 stock exchange data. View the 2137 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Brii Biosciences Ltd real time stock price chart below.
What Is the Brii Biosciences Ltd Stock Price Today?
The Brii Biosciences Ltd stock price today is 0.88.
What Is the Stock Symbol for Brii Biosciences Ltd?
The stock symbol for Brii Biosciences Ltd is "2137."
What Stock Exchange Does Brii Biosciences Ltd Trade On?
Brii Biosciences Ltd is listed and trades on the Hong Kong stock exchange.
Is Brii Biosciences Ltd a Good Stock to Buy?
Determining whether Brii Biosciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2137 quote. (ISIN: KYG1645A1094)
What Is the Brii Biosciences Ltd Stock Price Today?
The Brii Biosciences Ltd stock price today is 0.88.
What Is the Stock Symbol for Brii Biosciences Ltd?
The stock symbol for Brii Biosciences Ltd is "2137."
What Stock Exchange Does Brii Biosciences Ltd Trade On?
Brii Biosciences Ltd is listed and trades on the Hong Kong stock exchange.
Is Brii Biosciences Ltd a Good Stock to Buy?
Determining whether Brii Biosciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2137 quote. (ISIN: KYG1645A1094)
Hong Kong
Currency in HKD
0.88
-0.01(-1.12%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.85
0.88
52 wk Range
0.83
2.34
2137 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.850.88
52 wk Range
0.832.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2137 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low Price / Book multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Brii Biosciences Ltd Earnings Call Summary for H2/2025
- Brii Biosciences reported CNY 18.6M revenue in 2025 vs. zero in 2024, driven by Joincare Group licensing agreement upfront payment
- Strong cash position of CNY 1,941M ensures operational sustainability through 2028; R&D expenses declined 14.8% to CNY 212.9M
- Company projects revenue of USD 19.21M for 2026 and USD 19.19M for 2027, maintaining strategic focus on HBV functional cure programs
- Dr. Ankang Li appointed Chief Operating Officer; administrative expenses reduced 28.5% to CNY 199.5M through cost control measures
- Clinical trials for HBV treatment show promising results; company faces competition from bepirovirsen and xalnesiran in HBV market
Last Updated: 03/20/2026, 09:20 PM
Read Full TranscriptEarnings
Latest Release
Aug 20, 2026
EPS / Forecast
-0.07 / -0.11
Revenue / Forecast
-- / --
Compare 2137 to Peers and Sector
Metrics to compare | 2137 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2137PeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −21.7x | −0.4x | |
PEG Ratio | −0.06 | −0.14 | 0.00 | |
Price/Book | 0.2x | 4.3x | 2.6x | |
Price / LTM Sales | 15.2x | 13.3x | 3.1x | |
Upside (Analyst Target) | 134.5% | 41.9% | 57.4% | |
Fair Value Upside | Unlock | 0.9% | 7.7% | Unlock |
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Brii Biosciences (2137) Stock Price Today?
The Brii Biosciences stock price today is 0.88 HKD.
What Stock Exchange Does Brii Biosciences Trade On?
Brii Biosciences is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Brii Biosciences?
The stock symbol for Brii Biosciences is "2137."
What Is the Brii Biosciences Market Cap?
As of today, Brii Biosciences market cap is 635.23M HKD.
What Is Brii Biosciences's Earnings Per Share (TTM)?
The Brii Biosciences EPS (TTM) is -0.24.
When Is the Next Brii Biosciences Earnings Date?
Brii Biosciences will release its next earnings report on Dec 02, 2026.
From a Technical Analysis Perspective, Is 2137 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Brii Biosciences Stock Split?
Brii Biosciences has split 0 times.
How Many Employees Does Brii Biosciences Have?
Brii Biosciences has 80 employees.
What is the current trading status of Brii Biosciences (2137)?
As of Sep 28, 2026, Brii Biosciences (2137) is trading at a price of 0.88 HKD, with a previous close of 0.88 HKD. The stock has fluctuated within a day range of 0.85 HKD to 0.88 HKD, while its 52-week range spans from 0.83 HKD to 2.34 HKD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.